At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Clobazamdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.·interventional·Posted Dec 13, 2017·Updated Mar 4, 2021
In Brief
A Phase 4 clinical trial evaluating Clobazam for Epilepsy and Anxiety. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study is an open label, adjunctive, proof of concept, pilot clinical trial. Pediatric patients with epilepsy and clinically significant anxiety will be recruited and if enrolled will receive active treatment, involving flexible dose titration of clobazam and will be monitored for a period of four months. The study will be monitored and overseen by the Johns Hopkins Hospital Institutional Review Board.
Study Details
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedDec 2017
Primary CompletionDec 2019
TodayJul 2026
First PostedDec 13, 2017
Enrollment StartOct 1, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 8.6 years ago
Interventions
Clobazamdrug
Clobazam is used as an adjunct medicine for all participants.